NASDAQ: NGNE

Neurogene Inc.

Healthcare | Biotechnology

Market prices for NGNE are shown to signed-in users (sign in). This public page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2024)$-4.28

Neurogene Inc. (NASDAQ: NGNE) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 04:32 UTC.

What Neurogene Inc. does

Neurogenesis Therapeutics is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases that cannot be effectively treated with conventional gene therapy. The company uses proprietary transgene regulation technology called EXACT, which employs microRNA-based genetic circuits to deliver therapeutic levels of treatment to affected brain regions.

Summarized from Neurogene Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation	8-K 2026-07-02
EPS (FY2024)	$-4.28

Charts

Charts are in the appInteractive charts for NGNE are available in Oxford Ledge.
Open NGNE in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-02

2026-10-02Chief Executive OfficerStock Option (Right to Buy)Option exercise-756—
2026-10-02Chief Executive OfficerOption exercise756$19.1K
2026-07-07President and CFOSale-4,200$151.8K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

SAMSARA BIOCAPITAL, LLC1,717,127$54.00M0.0%
Casdin Capital, LLC1,545,361$48.60M+8.8%
Redmile Group, LLC1,412,199$44.41M-3.2%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2024-04-02Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersMcMinn's Employment AgreementAuthoritativeSEC 8-K →
2024-02-21Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2023-04-03Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Neurogene GAAP EPS of -$1.05 beats by $0.37
Seeking Alpha Markets2026-08-11POS
Canaccord Genuity Maintains Buy on Neurogene, Lowers Price Target to $180
Benzinga2026-04-06
Neurogene shares are trading higher. The company, on Tuesday, reported Q4 financial results.
Benzinga2026-03-25
Neurogene Q4 EPS $(1.13), Inline
Benzinga2026-03-24

Questions this page answers

What does Neurogene Inc. do?

Neurogenesis Therapeutics is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases that cannot be effectively treated with conventional gene therapy.

When did NGNE last file with the SEC?

Neurogene Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-02. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 04:32 UTC. This page is also available as JSON at /api/data?ticker=NGNE and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for NGNE and 5,000+ tickers.

Create a free account — keep NGNE

For your agent

GET /api/data?ticker=NGNE

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt